Immunoassay Test Types and Clinical Applications

Immunoassays are laboratory techniques that use the binding between antibodies and antigens to detect and quantify analytes in biological samples. These methods underpin a substantial portion of clinical diagnostics, including hormone testing, infectious disease screening, cardiac marker measurement, and therapeutic drug monitoring. This article provides a comparative overview of the major immunoassay formats, including enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), fluorescence immunoassay (FIA), chemiluminescent immunoassay (CLIA), and lateral flow assays, with practical guidance for selecting an appropriate method based on analyte characteristics, required sensitivity, sample type, and laboratory throughput.

Laboratory students, technicians, researchers, and diagnostic professionals must understand that no single immunoassay format serves all clinical situations. Each technique carries distinct strengths and limitations regarding sensitivity, specificity, cost, automation potential, and susceptibility to interference. The decision framework presented here supports method selection and troubleshooting in clinical and research laboratory settings.

At a Glance

The table below summarizes the principal immunoassay formats, their typical applications, relative sensitivity, throughput, and practical considerations. This comparison supports initial method selection decisions.

The World Health Organization Laboratory Quality Management System Handbook provides foundational guidance on implementing quality practices across all laboratory testing methods, including immunoassays. Laboratories should consult this resource when establishing or auditing their immunoassay procedures. The handbook is available at WHO Laboratory Quality Management System Handbook.

Core Principles of Immunoassay Design

Immunoassays rely on the specific recognition of an analyte by an antibody. The antibody binds to the target molecule, and the resulting antibody-antigen complex is detected through a label that produces a measurable signal. The label may be an enzyme, a radioisotope, a fluorophore, a chemiluminescent compound, or a colloidal particle.

Antibody Types and Selection

Monoclonal antibodies recognize a single epitope on the target analyte, providing high specificity. Polyclonal antibodies recognize multiple epitopes and may offer greater robustness against minor structural variations in the analyte. The choice between monoclonal and polyclonal reagents affects assay specificity, batch consistency, and cost. Sandwich immunoassays use a capture antibody immobilized on a solid phase and a detection antibody conjugated to a label. Competitive immunoassays use a single antibody and a labeled analyte that competes with the unlabeled analyte in the sample.

Solid Phase Formats

Microtiter plates, magnetic beads, membranes, and flow cells serve as solid phases for immunoassays. The solid phase enables separation of bound from free analyte, a critical step in heterogeneous assays. Microtiter plates support high-throughput testing in 96-well or 384-well formats. Magnetic beads increase surface area and accelerate reaction kinetics. Membranes form the basis of lateral flow devices. The choice of solid phase influences assay sensitivity, washing efficiency, and automation compatibility.

Signal Generation and Measurement

Enzyme labels such as horseradish peroxidase and alkaline phosphatase convert substrates into colored, fluorescent, or chemiluminescent products. The amount of signal generated is proportional to the quantity of analyte in the sample. Fluorescent labels emit light at specific wavelengths when excited by light of another wavelength. Chemiluminescent labels emit light through a chemical reaction without requiring an excitation source. Radioisotopic labels emit radiation that is measured by gamma counters or scintillation counters. Each label type requires specific detection instrumentation and contributes to the overall assay performance characteristics.

Enzyme-Linked Immunosorbent Assay

ELISA is one of the most widely used immunoassay formats in clinical and research laboratories. The technique uses enzyme-labeled antibodies or antigens and a chromogenic, fluorogenic, or chemiluminescent substrate to produce a measurable signal.

ELISA Variants

Direct ELISA uses an enzyme-labeled antibody that binds directly to the antigen immobilized on the plate. Indirect ELISA uses an unlabeled primary antibody followed by an enzyme-labeled secondary antibody that recognizes the primary antibody. Sandwich ELISA uses a capture antibody to immobilize the analyte and a detection antibody to quantify it. Competitive ELISA uses a labeled analyte that competes with sample analyte for a limited number of antibody binding sites.

Performance Characteristics

ELISA provides moderate to high sensitivity depending on the specific format and reagents. The National Center for Advancing Translational Sciences Assay Guidance Manual offers detailed protocols and validation considerations for ELISA and other assay formats. This resource supports assay development and troubleshooting in translational research settings. The manual is accessible at Assay Guidance Manual.

A comparative review of ELISA and chemiluminescent immunoassay found that CLIA is highly sensitive, specific, and rapid compared to ELISA, but CLIA is more expensive. This comparison is detailed in the Enzyme-Linked Immunosorbent Assay versus Chemiluminescent Immunoassay overview. Laboratories with high test volumes and available capital may prefer CLIA platforms, while laboratories with lower volumes or limited budgets may find ELISA more practical.

ELISA in Salivary Diagnostics

ELISA has been applied to salivary biomarker detection. A review of extraoral detection techniques reported that ELISA and direct surface-enhanced Raman spectroscopy achieved balanced accuracy of approximately 87% in clinical studies. The same review noted that electrochemical platforms demonstrated the highest sensitivity for cortisol detection in saliva, with a geometric mean limit of detection of 11 pM, followed by immunoassay-based platforms at 39.1 pM and mass spectrometry at 171 pM. These findings are presented in the Extraoral Detection of Biomarkers and Pathogens in Saliva review. Laboratories considering salivary testing should evaluate whether ELISA sensitivity meets the clinical requirements for their target analytes.

ELISA for Rotavirus Typing

ELISA has been compared with molecular methods for rotavirus genotyping. A study evaluating enzyme immunoassay, PCR, and hybridization techniques for identifying group A rotavirus P types found sensitivities and specificities of 92% and 92% for reverse transcription-PCR, 80% and 99% for hybridization, and 73% and 91% for ELISA with neutralizing monoclonal antibodies. The study is reported in the Journal of Clinical Microbiology comparison of rotavirus typing methods. This example illustrates that ELISA may have lower sensitivity than molecular methods for certain applications, and laboratories should verify assay performance for their specific diagnostic question.

Radioimmunoassay

Radioimmunoassay was among the first immunoassay formats developed and remains in use for specific applications where its sensitivity and specificity are advantageous. RIA uses radioisotopically labeled antigens or antibodies, typically iodine-125, to measure analyte concentrations.

Operational Requirements

RIA requires specialized facilities, licensing for radioactive material use, and specific waste disposal procedures. The World Health Organization Laboratory Biosafety Manual provides guidance on safe handling of radioactive materials and other biological hazards in laboratory settings. Laboratories considering RIA must implement appropriate safety protocols and staff training. The manual is available at WHO Laboratory Biosafety Manual.

Current Utility

The use of RIA has declined in many clinical laboratories due to the availability of non-isotopic alternatives with comparable sensitivity and fewer regulatory burdens. However, RIA remains valuable for certain hormone measurements and research applications where established protocols and reference ranges exist. Laboratories maintaining RIA capabilities must ensure ongoing staff competency, instrument calibration, and compliance with radiation safety regulations.

Fluorescence Immunoassay

Fluorescence immunoassay uses fluorescent labels to detect and quantify analytes. The technique offers high sensitivity and supports both heterogeneous and homogeneous assay formats.

Fluorescent Labels

Fluorescent labels include fluorescein, rhodamine, and various cyanine dyes. The choice of fluorophore affects excitation and emission wavelengths, photostability, and susceptibility to background interference. A review of fluorescent labels in immunoassay discusses the utility and limitations of these labels in different assay configurations. The review is available at On the use of fluorescent labels in immunoassay.

Fluorescence-Based Detection Methods

Surface-enhanced fluorescence and surface-enhanced Raman spectroscopy represent advanced detection approaches for immunoassays. A study comparing these methods for survivin detection on nanostructured silver substrates achieved a detection limit of 12.5 pg/mL with both approaches and a linear dynamic range up to 500 pg/mL. The study demonstrated application to human serum samples from healthy and ovarian cancer patients. These findings are reported in the Biosensors comparison of survivin detection methods. Laboratories pursuing high-sensitivity protein detection may consider these advanced fluorescence-based approaches.

Quenchbody-Based Fluorescence Detection

A quenchbody-based method for L-thyroxine detection has been developed and compared with ELISA systems. The method uses antibody fragments labeled with fluorescent dyes that are quenched in the absence of analyte and emit fluorescence upon analyte binding. The comparison is described in the Analytical and Bioanalytical Chemistry study on quenchbody-based L-thyroxine detection. This approach offers a homogeneous assay format that may simplify workflow compared to traditional ELISA.

Chemiluminescent Immunoassay

Chemiluminescent immunoassay uses chemical reactions that emit light to quantify analytes. CLIA has become a dominant format in automated clinical chemistry analyzers due to its high sensitivity, wide dynamic range, and compatibility with high-throughput testing.

CLIA Platforms

Automated CLIA platforms integrate reagent handling, incubation, washing, signal detection, and result calculation. These systems reduce manual steps and improve reproducibility. The Enzyme-Linked Immunosorbent Assay versus Chemiluminescent Immunoassay overview notes that CLIA is highly sensitive, specific, and rapid compared to ELISA, but the instrument and reagent costs are higher.

CLIA for Vaccine Response Monitoring

CLIA has been used to measure antibody responses following vaccination. A study using chemiluminescent microparticle immunoassay measured anti-RBD IgG levels in 2065 blood bank donors and healthcare workers who received different COVID-19 vaccines. The study found that mean antibody titers varied significantly among vaccine types, with the highest titers observed after a third booster dose. Antibody levels in the Pfizer group were highest initially but began to decline after 60 days, while AstraZeneca and Sinopharm vaccine-induced antibodies remained stable until 120 days at lower levels. These findings are reported in the Vaccine study on anti-RBD IgG antibody response. This application demonstrates the utility of CLIA for population-level serological monitoring.

Lateral Flow Assays

Lateral flow assays are point-of-care immunoassays that provide rapid results without specialized instrumentation. These devices use capillary flow to transport the sample across a membrane containing immobilized antibodies and labeled detection reagents.

Design and Operation

A lateral flow device typically contains a sample pad, conjugate pad, nitrocellulose membrane, and absorbent pad. The sample is applied to the sample pad and migrates through the device. Analyte in the sample binds to labeled antibodies on the conjugate pad, and the complex is captured by immobilized antibodies on the test line. A control line confirms proper device function.

Performance in Clinical Applications

Lateral flow assays have been evaluated for various diagnostic applications. A study comparing the LDBio Aspergillus immunochromatographic lateral flow assay across three sample types for IgG/IgM antibody detection in chronic aspergillosis is documented in the Clinical Microbiology and Infection publication. The study examined sample type effects on assay performance.

A comparison of the NG-Test Carba 5, colloidal gold immunoassay, and Xpert Carba-R for carbapenemase detection in 207 Gram-negative strains found accuracies of 96.88%, 96.88%, and 97.92%, respectively. The NG-Test Carba 5 performed best for strains carrying multiple carbapenemase genes, accurately identifying all target genes in 15 strains with two or three carbapenemase genes, compared to 12 of 15 for Xpert Carba-R and 10 of 15 for the colloidal gold immunoassay. These findings are reported in the Antibiotics comparison of carbapenemase detection methods. Laboratories selecting lateral flow assays for antimicrobial resistance detection should consider the target gene coverage and performance with mixed infections.

Specimen Type Effects

Specimen type significantly affects lateral flow assay performance. A study comparing the FLU OIA optical immunoassay with cell culture for influenza detection across four specimen types found that sputum and nasal aspirates were the most predictive of influenza infection, while throat swabs were the least predictive, with both tests failing to detect influenza in nearly 50% of throat samples. These findings are reported in the Journal of Clinical Microbiology study on influenza specimen types. Laboratories using lateral flow assays for respiratory virus detection should prioritize appropriate specimen collection to maximize diagnostic sensitivity.

Amperometric Immunoassay

Amperometric immunoassay uses electrochemical detection to measure analytes. The technique offers high sensitivity, rapid analysis, and compatibility with miniaturized biosensor formats.

Principles and Applications

Amperometric immunoassays measure the current generated by an electrochemical reaction at an electrode surface. Enzyme labels such as horseradish peroxidase or glucose oxidase generate electroactive products that produce measurable current. A review of amperometric immunoassay describes the utility, ease, speed, and simplicity of the technique, along with its limitations compared to other analytical methods. The review covers electrode types, assay design, automation, and applications. It is available at Amperometric immunoassay review.

Biosensor Integration

Amperometric immunoassays are well suited for integration into biosensor devices for point-of-care testing. The Emerging point-of-care technologies for bacterial pathogen detection review discusses immunoassay-based platforms alongside molecular and phenotypic methods for bacterial detection. The review emphasizes the need for evidence-based frameworks for selecting detection targets and matching them to appropriate point-of-care modalities.

Seeding Amplification ImmunoAssay

Seeding amplification immunoassay represents an emerging format that combines immunoassay principles with amplification of disease-specific protein aggregates. A study introducing SAIA for detecting α-synuclein seeds in cerebrospinal fluid reported sensitivities and specificities ranging from 80% to 100% with area under the curve values exceeding 0.9 for distinguishing synucleinopathies from non-synucleinopathies and controls. The assay accurately identified 24 of 24 idiopathic REM sleep behavior disorder cases with 100% sensitivity and 80% specificity. These findings are reported in the Journal of Parkinson's Disease study on SAIA. This format demonstrates the potential for quantitative, high-throughput detection of protein aggregation disorders.

Method Selection Framework

Selecting an appropriate immunoassay format requires systematic evaluation of multiple factors. The following framework supports method selection decisions in clinical and research laboratories.

Step 1: Define the Analytical Requirement

Document the analyte of interest, expected concentration range in the relevant sample matrix, required sensitivity and specificity, and clinical or research decision thresholds. Consult published literature and reference laboratory data to establish performance targets.

Step 2: Evaluate Sample Type and Volume

Consider the sample matrix, available volume, and collection constraints. Saliva offers non-invasive collection but may require higher sensitivity methods for low-abundance analytes. The Extraoral Detection of Biomarkers and Pathogens in Saliva review provides comparative sensitivity data for different detection platforms in saliva. Serum and plasma are standard for most immunoassays, while urine and cerebrospinal fluid present matrix-specific considerations.

Step 3: Assess Throughput and Turnaround Requirements

Estimate daily test volume and required turnaround time. Automated CLIA platforms support high-throughput testing with rapid results. ELISA provides moderate throughput with plate-based processing. Lateral flow assays offer rapid results for individual or small batches of samples. The Enzyme-Linked Immunosorbent Assay versus Chemiluminescent Immunoassay overview compares throughput and cost characteristics of these formats.

Step 4: Consider Interference Susceptibility

Evaluate the potential for assay interference from endogenous antibodies, biotin, and other sample components. A review of thyroid function immunoassays identified six main types of interference: macro-TSH, biotin, antistreptavidin antibodies, anti-ruthenium antibodies, thyroid hormone autoantibodies, and heterophilic antibodies. The review reported that at least 50% of documented thyroid interferences led to misdiagnosis or inappropriate management. These findings are detailed in the Endocrine Reviews publication on thyroid function immunoassay interference.

A similar review of parathyroid hormone measurement identified heterophilic antibodies, biotin, PTH fragments, oxidized PTH, phosphorylated PTH, and preanalytical factors as sources of interference. The review noted that some of these conditions may approach 11.7% prevalence and can lead to misdiagnosis, inappropriate parathyroidectomy, and delayed therapy. These findings are reported in the Clinica Chimica Acta publication on PTH measurement.

Step 5: Calculate Cost and Resource Requirements

Compare instrument acquisition costs, reagent costs per test, consumables, maintenance, and staffing requirements. CLIA platforms require significant capital investment but offer lower per-test costs at high volumes. ELISA requires less capital but more manual labor. Lateral flow assays have low per-test costs but may have higher per-test sensitivity limitations.

Step 6: Verify Performance Characteristics

Before implementing a new immunoassay, verify performance characteristics including accuracy, precision, sensitivity, specificity, linearity, and robustness. The U.S. Food and Drug Administration Bioanalytical Method Validation Guidance provides a framework for validating analytical methods used in clinical and regulatory settings. This guidance is available at FDA Bioanalytical Method Validation Guidance.

Records and Measurements

Maintaining accurate records is essential for immunoassay quality management. The following records should be maintained for each assay run and over time.

Assay Run Records

Document the date, operator, reagent lot numbers, calibration curve data, quality control results, and patient or sample results for each assay run. Record any deviations from standard procedures and corrective actions taken. These records support troubleshooting and audit readiness.

Quality Control Records

Maintain quality control charts showing results for control materials at multiple concentration levels. Monitor trends and shifts in control values that may indicate reagent degradation, instrument drift, or procedural errors. The World Health Organization Laboratory Quality Management System Handbook provides guidance on quality control practices for laboratory testing. The handbook is available at WHO Laboratory Quality Management System Handbook.

Instrument Maintenance Records

Document scheduled maintenance, calibration, and repairs for all immunoassay instruments. Record any performance issues and their resolution. Regular maintenance prevents instrument-related assay failures and extends equipment life.

Interference Investigation Records

When assay interference is suspected, document the clinical or biochemical discrepancy, the investigation steps taken, and the outcome. The detection algorithms described in the Endocrine Reviews publication on thyroid interference and the Clinica Chimica Acta publication on PTH interference provide structured approaches to interference identification.

Common Failure Patterns

Immunoassay failures can arise from multiple sources. Recognizing common failure patterns supports efficient troubleshooting.

Hook Effect

The hook effect occurs when extremely high analyte concentrations saturate antibody binding sites, producing falsely low results. This phenomenon is most common in sandwich immunoassays. Laboratories should be aware of this limitation and consider dilution protocols for samples with suspected high analyte concentrations.

Matrix Effects

Sample matrix components can interfere with antibody binding or signal detection. Hemolysis, lipemia, and icterus may affect assay performance. Saliva and urine present matrix-specific challenges due to their complex composition. The Extraoral Detection of Biomarkers and Pathogens in Saliva review discusses matrix considerations for salivary testing.

Heterophilic Antibody Interference

Heterophilic antibodies can bridge capture and detection antibodies in sandwich immunoassays, producing false positive results. The Endocrine Reviews publication on thyroid interference and the Clinica Chimica Acta publication on PTH interference describe blocking reagent studies and other methods for identifying heterophilic antibody interference.

Biotin Interference

Biotin supplementation can interfere with immunoassays that use biotin-streptavidin binding. High biotin concentrations in patient samples can produce falsely elevated or falsely decreased results depending on the assay format. Laboratories should inquire about biotin supplementation when results do not match clinical presentation.

Reagent Instability

Enzyme labels, antibodies, and substrates can degrade over time or with improper storage. Monitor reagent performance through quality control results and replace reagents according to manufacturer recommendations.

Instrument Malfunction

Pipetting errors, temperature fluctuations, and detector failures can produce erroneous results. Regular instrument maintenance and calibration prevent many instrument-related failures.

Limitations and Interpretation Guidance

Immunoassay results must be interpreted in the context of assay limitations and clinical presentation. The following considerations support appropriate result interpretation.

Sensitivity Limitations

Each immunoassay format has a limit of detection below which analyte cannot be reliably distinguished from zero. The Extraoral Detection of Biomarkers and Pathogens in Saliva review provides comparative limit of detection data for different detection platforms. Laboratories should verify that assay sensitivity meets clinical requirements for the intended use.

Specificity Limitations

Cross-reactivity with structurally similar compounds can produce falsely elevated results. Antibody selection and assay design influence specificity. Laboratories should review manufacturer data on cross-reactivity and consider confirmatory testing when results are unexpected.

Reference Range Considerations

Reference ranges vary by population, sample type, and assay method. Laboratories should establish or verify reference ranges for their specific assay and patient population. Results near reference range boundaries require careful interpretation.

Interference Awareness

The Endocrine Reviews publication on thyroid interference emphasizes that potential interferences should always be suspected whenever clinical or biochemical discrepancies arise. The review proposes a detection algorithm based on the pattern of thyroid function test alterations to screen for six types of interference. Similarly, the Clinica Chimica Acta publication on PTH interference recommends method comparison, serial dilution, blocking reagent studies, affinity adsorption, and polyethylene glycol precipitation for interference identification.

Confirmatory Testing

When immunoassay results conflict with clinical presentation, confirmatory testing using an alternative method may be necessary. Mass spectrometry offers an interference-resistant alternative for some analytes. The Clinica Chimica Acta publication on PTH measurement notes that some interference issues can be mitigated with the development of mass spectrometry methods.

Safety and Regulatory Context

Immunoassay laboratories must operate within applicable safety and regulatory frameworks.

Biosafety Considerations

The World Health Organization Laboratory Biosafety Manual provides guidance on safe handling of biological samples, reagents, and waste. Laboratories should implement appropriate biosafety levels based on the samples and organisms handled. The manual is available at WHO Laboratory Biosafety Manual.

Radioactive Material Safety

Laboratories using radioimmunoassay must comply with radiation safety regulations, including licensing, personnel monitoring, and waste disposal requirements. Staff must receive appropriate training in radioactive material handling.

Quality Management

The World Health Organization Laboratory Quality Management System Handbook provides a framework for implementing quality systems in laboratories. Key elements include document control, personnel competency, equipment maintenance, quality control, and proficiency testing. The handbook is available at WHO Laboratory Quality Management System Handbook.

Method Validation

The U.S. Food and Drug Administration Bioanalytical Method Validation Guidance describes validation requirements for analytical methods used in regulatory submissions. Key parameters include accuracy, precision, selectivity, sensitivity, reproducibility, and stability. This guidance is available at FDA Bioanalytical Method Validation Guidance.

Professional Escalation Criteria

Laboratory professionals should escalate immunoassay results or issues to clinical colleagues or supervisors under specific circumstances.

Clinical Discrepancy

When immunoassay results do not match the clinical presentation, notify the ordering clinician and discuss potential interference. The Endocrine Reviews publication on thyroid interference emphasizes that strong interaction between the clinician and the laboratory is necessary to avoid diagnostic pitfalls.

Unexpected Results

When results are outside the expected range, exceed the assay measuring interval, or conflict with previous results, investigate before reporting. Consider sample dilution, repeat testing, or alternative method confirmation.

Quality Control Failure

When quality control results fall outside acceptable limits, do not report patient results. Investigate the cause, document corrective actions, and repeat the assay after resolution.

Instrument Malfunction

When instrument errors or malfunctions occur, follow established procedures for troubleshooting and escalation. Document the issue and any impact on patient results.

Interference Suspected

When interference is suspected based on the pattern of results, initiate the appropriate detection algorithm. The Endocrine Reviews publication on thyroid interference and the Clinica Chimica Acta publication on PTH interference describe structured approaches to interference identification.

Frequently Asked Questions

What is the difference between competitive and sandwich immunoassays?

Competitive immunoassays use a single antibody and a labeled analyte that competes with the sample analyte for binding sites. These assays are typically used for small molecules with a single epitope. Sandwich immunoassays use a capture antibody and a detection antibody that bind to different epitopes on the analyte. These assays are used for larger molecules such as proteins and hormones and generally provide higher sensitivity and specificity.

Which immunoassay format provides the highest sensitivity?

Chemiluminescent immunoassay and advanced fluorescence-based methods generally provide the highest sensitivity among commercially available formats. The Enzyme-Linked Immunosorbent Assay versus Chemiluminescent Immunoassay overview reports that CLIA is highly sensitive compared to ELISA. Emerging formats such as seeding amplification immunoassay achieve detection at attogram levels for specific applications, as described in the Journal of Parkinson's Disease study.

How do I choose between ELISA and CLIA for my laboratory?

Consider test volume, available capital, required turnaround time, and per-test costs. ELISA requires lower capital investment but more manual labor and longer turnaround times. CLIA requires significant instrument investment but supports high-throughput testing with rapid results. The Enzyme-Linked Immunosorbent Assay versus Chemiluminescent Immunoassay overview provides a comparison of these formats.

What causes falsely elevated or decreased immunoassay results?

Common causes include heterophilic antibodies, biotin supplementation, autoantibodies, the hook effect, and matrix effects. The Endocrine Reviews publication on thyroid interference describes six main types of interference affecting thyroid function immunoassays. The Clinica Chimica Acta publication on PTH measurement describes similar interference sources for parathyroid hormone assays.

How do I investigate suspected immunoassay interference?

Begin with method comparison using an alternative assay platform, serial dilution studies, blocking reagent experiments, and polyethylene glycol precipitation. The Endocrine Reviews publication on thyroid interference proposes a detection algorithm based on the pattern of test alterations. The Clinica Chimica Acta publication on PTH measurement recommends affinity adsorption and mass spectrometry as additional investigation tools.

What specimen types are suitable for immunoassay testing?

Serum, plasma, urine, saliva, cerebrospinal fluid, and other biological fluids can be used depending on the assay and analyte. The Extraoral Detection of Biomarkers and Pathogens in Saliva review discusses the advantages of saliva for non-invasive testing. The Journal of Clinical Microbiology study on influenza specimen types demonstrates that specimen type significantly affects diagnostic sensitivity for respiratory virus testing.

Are lateral flow assays as accurate as laboratory-based immunoassays?

Lateral flow assays provide rapid results but may have lower sensitivity than laboratory-based formats. The Antibiotics comparison of carbapenemase detection methods found that the NG-Test Carba 5 and colloidal gold immunoassay achieved 96.88% accuracy compared to 97.92% for the molecular Xpert Carba-R assay. Performance varies by application and target analyte.

How should I validate an immunoassay before clinical use?

Follow the U.S. Food and Drug Administration Bioanalytical Method Validation Guidance, which describes requirements for accuracy, precision, selectivity, sensitivity, reproducibility, and stability. This guidance is available at FDA Bioanalytical Method Validation Guidance. The National Center for Advancing Translational Sciences Assay Guidance Manual also provides practical protocols for assay development and validation, accessible at Assay Guidance Manual.

Related Diagnostic Guides

• Digital Droplet PCR (ddPCR) for Absolute Quantification of Swine Enteric Coronaviruses in Fecal and Oral Fluid Samples: Analytical Sensitivity and Clinical Utility
• CRISPR-Based Diagnostics for Avian Influenza
• Spread Plate Method: Protocol, Advantages, and Applications
• How to Perform an Antibiotic Susceptibility Test Using the Etest Method
• How to Perform a Capsule Test in Microbiology: Negative Staining Method

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Interferences With Thyroid Function Immunoassays: Clinical Implications and Detection Algorithm.. Endocrine reviews, 2018.
• Cellular neurothekeoma.. Applied pathology, 1986.
• Amperometric immunoassay.. Critical reviews in clinical laboratory sciences, 1990.
• Preanalytical considerations in parathyroid hormone measurement.. Clinica chimica acta, international journal of clinical chemistry, 2023.
• Comparison of three sample types for performing LDBio Aspergillus immunochromatographic technology lateral flow assay for IgG/IgM antibody detection in chronic aspergillosis.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2023.
• Comparison of enzyme immunoassay, PCR, and type-specific cDNA probe techniques for identification of group A rotavirus gene 4 types (P types).. Journal of clinical microbiology, 1997.
• Quantitative measurements of α-synuclein seeds in CSF inform diagnosis of synucleinopathies.. Journal of Parkinson's disease, 2025.
• Comparison of four clinical specimen types for detection of influenza A and B viruses by optical immunoassay (FLU OIA test) and cell culture methods.. Journal of clinical microbiology, 1999.
• Extraoral Detection of Biomarkers and Pathogens in Saliva: Comprehensive, Panoramic Review.. 2026.
• Cortisol as a stress biomarker: analytical perspectives and challenges.. 2026.
• Emerging point-of-care technologies for bacterial pathogen detection.. 2026.
• Comparison of the NG-Test Carba 5, Colloidal Gold Immunoassay (CGI) Test, and Xpert Carba-R for the Rapid Detection of Carbapenemases in Carbapenemase-Producing Organisms. Antibiotics, 2023.
• Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies. Vaccine, 2022.
• Enzyme-Linked Immunosorbent Assay versus Chemiluminescent Immunoassay: A General Overview. Global Journal of Medical, Pharmaceutical, and Biomedical Update, 2023.
• Comparison of Survivin Determination by Surface-Enhanced Fluorescence and Raman Spectroscopy on Nanostructured Silver Substrates. Biosensors, 2024.
• Establishment of a Quenchbody-based L-thyroxine detection method and its comparison with ELISA systems. Analytical and Bioanalytical Chemistry, 2024.
• On the use of fluorescent labels in immunoassay. Journal of Pharmaceutical and Biomedical Analysis, 1987.
• Determination of isoprostaglandin F2α type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay. Journal of Chromatography B Biomedical Sciences and Applications, 2001.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.